SAN FRANCISCO, Dec. 5, 2017 /PRNewswire/ -- Shareholder and
consumer rights law firm Schubert Jonckheer & Kolbe LLP has
launched an investigation into whether certain officers and
directors of PTC Therapeutics, Inc. (NASDAQ: PTCT) breached their
fiduciary duties by causing the company to issue false and
misleading statements. PTC develops drugs that treat rare diseases
and disorders.
On August 28, 2017, the United
States District Court for the District of New
Jersey issued an order denying in part the motion to dismiss
securities fraud class action claims against PTC and certain of its
executives. The operative complaint in that action, filed on
January 13, 2017, alleges that during
the period November 6, 2014 through February 23, 2016, the defendants misrepresented
key aspects of PTC's business, thereby inflating the company's
stock price. Specifically, defendants allegedly made false and
misleading statements that certain clinical trial results
demonstrated the efficacy of its key genetic mutation drug, causing
stock losses when the truth was finally revealed.
Schubert Jonckheer & Kolbe's investigation concerns when and
how much certain of PTC's officers and directors knew about these
practices. Shareholders interested in seeking the recovery of
damages on behalf of PTC and securing other remedial measures
should contact the firm.
If you are a long-term holder of PTC stock and wish to obtain
additional information about Schubert Jonckheer & Kolbe's
investigation and your legal rights, please contact us via
email at wjonckheer@schubertlawfirm.com or by telephone
at (415) 788-4220, or fill out the form on our website
at http://classactionlawyers.com/PTC.
About Schubert Jonckheer & Kolbe
Schubert Jonckheer & Kolbe has extensive experience in
prosecuting securities claims, representing investors throughout
the nation in securities and shareholder lawsuits. Attorney
advertising. Prior results do not guarantee similar
outcomes.
View original
content:http://www.prnewswire.com/news-releases/schubert-firm-launches-investigation-of-ptc-therapeutics-inc-executives-for-potential-breaches-of-fiduciary-duty-300566791.html
SOURCE Schubert Jonckheer & Kolbe